These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9488805)

  • 1. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell vaccination as a treatment modality for melanoma.
    Eubel J; Enk AH
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines against advanced melanoma.
    Blanchard T; Srivastava PK; Duan F
    Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing in on a melanoma skin cancer vaccine.
    Mayo Clin Health Lett; 2012 Oct; 30(10):4. PubMed ID: 23133855
    [No Abstract]   [Full Text] [Related]  

  • 9. Melanoma vaccines: achievements and perspectives.
    Brichard VG; Gérard C
    Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy for melanoma: how can tolerance be overcome?].
    Robert C
    Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunotherapy with allogeneic tumor cell vaccines: present status.
    Chan AD; Morton DL
    Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination for malignant melanoma: recent developments.
    Jäger D; Jäger E; Knuth A
    Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma vaccines.
    Chapman PB
    Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
    Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
    Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Active specific immunotherapy of malignant melanoma].
    Lotem M; Shiloni E; Ingber A; Peretz T
    Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
    [No Abstract]   [Full Text] [Related]  

  • 19. DC therapy for metastatic melanoma.
    Ingram SB; O'Rourke MG
    Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.